GlassScriptPhysician profile
Samuel Maurice Kohn
NPI 1548372600
$351.00
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $75.59 · 2021: $33.48.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $136.22 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.07 | 2019-2020 | |
| Glaxosmithkline, LLC. | $35.14 | 2019-2020 | |
| Neos Therapeutics, LP | $30.51 | 2019 | |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $21.87 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $17.67 | 2021 | |
| Aytu Biopharma, INC. | $15.88 | 2020 | |
| Tris Pharma INC | $15.81 | 2021 | |
| Rhodes Pharmaceuticals L.P. | $15.36 | 2019 | |
| Merck Sharp & Dohme LLC | $13.36 | 2019 | |
| Pfizer INC. | $13.11 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Kohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.